



RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 20784/5		SERIAL NO. 09/745,883	
				APPLICANT(S): Demuth et al.			
				FILING DATE: December 21, 2000		ART UNIT: 1653	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
CHK	AA	2,961,377	11/22/1960	Shapiro et al.	167	65	
---	AB	3,174,901	3/23/65	Sterne	167	65	
---	AC	3,879,541	4/22/1975	Kabbe et al.	424	326	
CHK	AD	3,960,949	6/1/1976	Ahrens et al.	260	564 B	
---	AE	4,028,402	6/7/1977	Fischer et al.	260	501.14	
CHK	AF	4,935,493	6-19-1990	Bachovchin et al	530	331	
---	AG	5,462,928	10/31/95	Bachovchin et al.	514	19	
CHK	AH	5,512,549	4-30-1996	Chen et al.	514	12	
---	AI	5,543,396	8/6/96	Powers et al.	514	19	
---	AJ	5,939,560	8/17/99	Jenkins et al.	548	535	
---	AK	6,006,753	12-28-1999	Efendic	128	898	

Demuth et al.
09/745,883
IDS
Page 2 of 6



RECEIVED
JUN 21 2002
TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 20784/5	SERIAL NO. 09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
_____	BA	WO 01/62266 A2	08/30/01	PCT	A61K	38/00	Y
CHK	BB	WO 00/53171	9/14/00	PCT	A61K	31/155	Y
CHK	BC	DT 25 42 598 A1	4/22/76	Germany	C07C	129/16	N
CHK	BD	FR 2 696 740 A1	4/15/94	France	C07D	207/404	N
CHK	BE	FR 2 085 665	12/31/71	France	A61K	27/00	N
CHK	BF	WO 97/40832	11/6/97	PCT	A61K	31/425	Abstract only
CHK	BG	WO 95/15309	6/8/95	PCT	C07D	207/16	Y
CHK	BH	JP 4334357	11/20/92	JAPAN	C07C	233/57	Abstract only
CHK	BI	WO 95/29691	11/09/95	PCT	A61K	38/00	Y
CHK	BJ	WO 98/22494	5/28/98	PCT	C07K	5/06	Y
_____	BK	WO 00/01849	01/13/00	PCT	C12Q	1/68	Y
CHK	BL	EP 0 658 568 A1	6/21/95	EPO	C07K	14/605	Y
_____	BM	DD 296 075 A5	11/21/91	Germany	C07D	295/04	Y
CHK	BN	DD 296 075 A5	11/21/91	Germany	C07D	295/04	N
CHK	BO	EP 0 708 179 A2	4/24/96	EPO	C12N	15/16	Y
_____	BP	EP 0 995 440 A1	4/26/00	EPO	A61K	31/425	N
_____	BQ	WO 91/11457	08/8/91	PCT	C07K	7/34	Y
_____	BR	WO 91/16339	10/31/91	PCT	C07K	5/10	Y
_____	BS	WO 98/19998	5/14/98	PCT	C07D	207/00	Y
_____	BT	WO 91/17767	11/28/91	PCT	A61K	37/54	Y


Demuth et al.
09/745,883
IDS
Page 3 of 6



RECEIVED
JUN 21 2002
TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 20784/5	SERIAL NO. 09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653


FOREIGN PATENT DOCUMENTS							
BU		JP 04-288098	10/13/92	JP	C07K	7/06	(Abstract Only)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
CMK	CA	Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, "Sulphonylureas and metformin: efficacy and inadequacy". 3:33-51 (1990).					
CMK	CB	The Merck Index, 11 th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, Page 934					
	CC	The Merck Index, 12 th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, Page 1014.					
CMK	CD	Martindale The Extra Pharmacopoeia, 30 th Edition, London Pharmaceutical Press, 1993, Page 1619.					
	CE	Martindale The Extra Pharmacopoeia, 30 th Edition, London Pharmaceutical Press, 1993, Page 36.					
CMK	CF	CHEMICAL ABSTRACTS, vol. 115. No. 15, 14. October 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes"					
CMK	CG	CHEMICAL ABSTRACTS, vol. 126, no. 2, 13. January 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides"					
CMK	CH	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21. Juni 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Hosoda, et al, "Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors", November 1992 (1992-11-20)					
CMK	CI	ARAI ET AL: "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain" CHEMICAL AND PHARMACEUTICAL BULLETIN., Bd. 41, No. 9, 1993, pages. 1583-1588.					
CMK	CJ	AMASHEH, S., et al., "Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes". J. Physiol. 504, 169-174 (1997)					
	CK	DURINX, C.; et al.; "Reference Values for Plasma Dipeptidyl-Pepidase IV activity and their Association with Other Laboratory Parameters". Clin Chem Lab Med 2001, February; 39 (2) :155-9, 1 page.					
	CL	GOSSRAU, R.; "Cytochemistry of Membrane Proteases". Histochem J, 1985, July; 17 (7) :737-71, 1 page.					



RECEIVED
JUN 21 2002
TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20784/5	09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
_____	CM	HAHN, T.; et al.; "Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae". Acta Histochem 1993, December, 1995 (2) :185-92, 1 page.
_____	CN	HEYMANN, E.; et al.; "Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation." Klin Wochenschr, 1984, January, 2;62 (1) :2-10, 1 page.
_____	CO	MAGYAR, C.E.; et al.; "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." Am J Physiol Renal Physiol, 2000, August; 279 (2) :F358-69, 1 page.
_____	CP	PAPIES, B.; et al.; "Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." Cor Vasa, 1991; 33 (3) :218-26, 1 page.
_____	CQ	QURESHI. N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock". Regul Pept, 1998, September 25; 75-76:215-20, 1 page.
_____	CR	Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pages 728-729.
_____	CS	The Merck Index, An Encyclopedia of Chemicals and Drugs, 9 th Edition, Merck & Co., Inc., 1976, page 773
_____	CT	C.J. Bailey et al., <u>New Antidiabetic Drugs</u> , Smith-Gordon Nishimura, 1990, p. 36.
CMK	CU	Hoffmann et al., <u>Journal of Chromatography A</u> , "Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary eletrophoresis", 1995, 716:355-362.
_____	CV	C.B. Welch, <u>Medical Management of Non-Insulin-Dependent (Type II) Diabetes</u> , 3 rd edition, American Diabetes Association, "Diagnosis and Classification" p. 3, 1994, Pharmacologic Intervention (1 page).
_____	CW	Mannucci et al., <u>Diabetes Care</u> , "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects", 24(3): 489-494, March 2001.
_____	CX	Stryer, <u>Biochemistry</u> 3 rd Ed., "Protein Conformation, Dynamics, and Function", 1988, p 191-193.
_____	CY	Pauly et al., <u>Regulatory Peptides</u> , "Abstracts Issue: Abstracts from the 11 th International Symposium on Regulatory Peptides", July 15, 1996, 64(1-3): 148 plus cover.
_____	CZ	Gutniak et al., <u>New England Journal of Medicine</u> , "Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus", 1992, 326: 1316-1322.



RECEIVED


JUN 21 2002

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20784/5	09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
CMK	CAA	Hendrick et al., <u>Metabolism – Clinical and Experimental</u> , “Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats”, January 1993, 42(1): 1-6.
CMK	CAB	Nauck et al., <u>Diabetologia</u> , “Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients”, 1993, 36: 741-744.
CMK	CAC	Gutniak et al., <u>Diabetes Care</u> , “Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM”, September 1994, 17(9): 1039-1044.
CMK	CAD	Deacon et al., <u>Journal of Clinical Endocrinology and Metabolism</u> , “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo”, 1995, 80(3): 952-957.
_____	CAE	H.A. Smith et al., <u>Veterinary Pathology</u> (fourth edition), “Diseases and Disorders of Metabolism: Deficiency Diseases”, 1972, p 1018-1020.
_____	CAF	G.G. Duncan, <u>Diseases of Metabolism (Asian edition)</u>, “Diabetes Mellitus”, 1966, p 951-957.
_____	CAG	T.J. Kieffer et al., “Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by DP IV”, <u>Endocrinology</u>, Vol. 136(8), 1995, p 3585-3596.
_____	CAH	C.F. Deacon et al., <u>Diabetes</u>, “Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded from the NH₂-Terminus in Type II Diabetic Patients and in Healthy Subjects”, September 1995, 44: 1126-1131.
CMK	CAI	Pauly et al., <u>Metabolism</u> , “Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide”, 1999, 48(3): 385-389.
_____	CAJ	Vidal, 1993, 69th Edition, p. 612-613.
_____	CAK	Goodman & Gilman’s <u>The Pharmacological Basis of Therapeutics</u>, Ninth Edition, 1996, p. 1510.
_____	CAL	Nathan et al., <u>Diabetes Care</u>, “Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects”, February 1992, 15(2): 270-275.
_____	CAM	Pschyrembel, <u>Kininisches Wörterbuch</u> 257, Auflage, 1994, 9 pages.
_____	CAN	Frohman et al., <u>Journal of Clin. Invest.</u>, “Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma in Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH₂ Terminus”, Volume 78, October 1986, p 906-913

Demuth et al.
09/745,883
IDS
Page 6 of 6



RECEIVED
JUN 21 2002
TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 20784/5	SERIAL NO. 09/745,883
	APPLICANT(S): Demuth et al.	
	FILING DATE: December 21, 2000	ART UNIT: 1653

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
CAO	CAO	Snow et al., <u>Advances In Medicinal Chemistry</u> , "Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents", Vol. 3, 1995, p 149-177.
<i>CHK</i>	CAP	Thorens et al., <u>Diabetes</u> , "Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM", 1993, 42:1219-1225.
CAQ	CAQ	Ashworth et al., <u>BIOORG. MED. CHEM. LETT.</u> , "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", 1996, 6(10): 1163-1166.
CAR	CAR	Endroczi et al., <u>ACTA PHYSIOL. HUNG.</u> , "Dipeptidyl peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn^{2+} in Vitro", 1990, 75(1): 35-44.
CAS	CAS	Lee, H.S. et al., "Cathepsin B Inhibitory Peptides Derived from β -Casein," Peptides 21 (2000) 807-809.
CAT	CAT	Edwards, J.V. et al., <u>J. Peptide Res.</u> , "Synthesis and Activity of NH_2 - and $COOH$ -Terminal Elastase Recognition Sequences on Cotton," 1999, 54: 536-543.
Examiner: <i>CHK</i>		Date: <i>1/10/03</i>